Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Alkermes Yönetim

Yönetim kriter kontrolleri 3/4

Alkermes' CEO'su Richard Pops, Sep2011 tarihinde atandı, in görev süresi 13.08 yıldır. in toplam yıllık tazminatı $ 9.44M olup, şirket hissesi ve opsiyonları dahil olmak üzere 12.5% maaş ve 87.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.72% ine doğrudan sahiptir ve bu hisseler $ 33.02M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.4 yıl ve 3.8 yıldır.

Anahtar bilgiler

Richard Pops

İcra Kurulu Başkanı

US$9.4m

Toplam tazminat

CEO maaş yüzdesi	12.5%
CEO görev süresi	13.1yrs
CEO sahipliği	0.7%
Yönetim ortalama görev süresi	5.4yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Richard Pops'un ücretlendirmesi Alkermes'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	US$386m
Mar 31 2024	n/a	n/a	US$570m
Dec 31 2023	US$9m	US$1m	US$519m
Sep 30 2023	n/a	n/a	US$412m
Jun 30 2023	n/a	n/a	US$300m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$10m	US$1m	-US$33m
Sep 30 2022	n/a	n/a	-US$129m
Jun 30 2022	n/a	n/a	-US$94m
Mar 31 2022	n/a	n/a	-US$62m
Dec 31 2021	US$9m	US$1m	US$76m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$63m
Mar 31 2021	n/a	n/a	-US$95m
Dec 31 2020	US$8m	US$1m	-US$111m
Sep 30 2020	n/a	n/a	-US$74m
Jun 30 2020	n/a	n/a	-US$126m
Mar 31 2020	n/a	n/a	-US$139m
Dec 31 2019	US$15m	US$1m	-US$197m
Sep 30 2019	n/a	n/a	-US$201m
Jun 30 2019	n/a	n/a	-US$183m
Mar 31 2019	n/a	n/a	-US$173m
Dec 31 2018	US$17m	US$1m	-US$139m
Sep 30 2018	n/a	n/a	-US$139m
Jun 30 2018	n/a	n/a	-US$141m
Mar 31 2018	n/a	n/a	-US$152m
Dec 31 2017	US$9m	US$964k	-US$158m

Tazminat ve Piyasa: Richard 'nin toplam tazminatı ($USD 9.44M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.79M ).

Tazminat ve Kazançlar: Richard 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Richard Pops (62 yo)

13.1yrs

Görev süresi

US$9,442,066

Tazminat

Mr. Richard F. Pops has been the Chief Executive Officer and Director of Alkermes PLC since September 2011 and its Chairman since September 16, 2011. Mr. Pops was the Founder of Genomics Collaborative, Inc...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Pops	Chairman & CEO	13.1yrs	US$9.44m	0.72% $ 34.0m
Blair Jackson	Interim Principal Financial Officer	3.8yrs	US$4.56m	0.096% $ 4.5m
David Gaffin	Executive VP	8.4yrs	US$4.14m	0.10% $ 4.8m
Iain Brown	Senior VP & CFO (Leave of Absence)	less than a year	US$3.21m	0.071% $ 3.4m
Craig Hopkinson	Executive VP of Research & Development and Chief Medical Officer	7.4yrs	US$4.23m	0.067% $ 3.2m
Floyd Bloom	Founder	no data	US$324.96k	Veri yok
Samuel Parisi	Interim Principal Accounting Officer & VP of Finance	less than a year	Veri yok	0.0047% $ 222.7k
Thomas Harvey	Chief Information Officer & Senior VP of IT	6.5yrs	Veri yok	Veri yok
Sandra Coombs	Senior Vice President of Corporate Affairs & Investor Relations	no data	Veri yok	Veri yok
Stephen Schiavo	Senior Vice President of Human Resources	4.3yrs	Veri yok	Veri yok
Peter Norman	Senior Vice President of Policy & Government Relations	no data	Veri yok	Veri yok
Declan O'Connor	Senior Vice President of Operations and Environment	no data	Veri yok	Veri yok

5.4yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: ALKS 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Richard Pops	Chairman & CEO	13.1yrs	US$9.44m	0.72% $ 34.0m
Brian McKeon	Independent Director	3.8yrs	US$482.04k	0.023% $ 1.1m
Nancy Snyderman	Independent Director	8.4yrs	US$482.04k	0.015% $ 733.0k
Nancy Lurker	Independent Director	less than a year	Veri yok	Veri yok
Shane Cooke	Independent Director	6.6yrs	US$449.04k	0.061% $ 2.9m
David Daglio	Independent Director	3.8yrs	US$474.04k	0.065% $ 3.1m
Cato Laurencin	Independent Director	2.9yrs	US$459.04k	0.012% $ 571.1k
Frank Wilson	Lead Independent Director	5.1yrs	US$486.65k	0.015% $ 720.7k
Christopher Wright	Independent Director	2.4yrs	US$463.12k	0.0088% $ 415.4k
Richard Brian Gaynor	Independent Director	5.1yrs	US$464.69k	0.015% $ 720.7k
Emily Alva	Independent Director	3.4yrs	US$469.04k	0.017% $ 787.1k

3.8yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ALKS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Alkermes Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Alkermes plc, Annual General Meeting, May 31, 2024

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Alkermes plc Announces Executive Changes

Alkermes plc Announces Changes to its Board

Alkermes plc, Annual General Meeting, Jun 29, 2023

Lead Independent Director notifies of intention to sell stock

Recent updates

Is Alkermes (NASDAQ:ALKS) A Risky Investment?

Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2

Alkermes: Fairly Valued After Post-Earnings Bump

Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry

The Bottom Fishing Club: Alkermes Has Great Value And Safety

Alkermes' (NASDAQ:ALKS) Solid Profits Have Weak Fundamentals

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Alkermes plc to Report Q1, 2024 Results on May 01, 2024

Alkermes plc, Annual General Meeting, May 31, 2024

Price target increased by 7.3% to US$35.50

Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data

Alkermes plc Announces Positive Topline Results from Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients with Narcolepsy Type 2 and Idiopathic Hypersomnia

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

New minor risk - Shareholder dilution

Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors

Consensus EPS estimates increase by 52%

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alkermes plc (NasdaqGS:ALKS) announces an Equity Buyback for $400 million worth of its shares.

Alkermes plc to Report Q4, 2023 Results on Feb 15, 2024

Alkermes plc Announces Executive Changes

Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet

Alkermes plc Announces Changes to its Board

Alkermes plc Revises Earnings Guidance for the Fiscal Year 2023

Is Alkermes (NASDAQ:ALKS) Using Too Much Debt?

Alkermes' (NASDAQ:ALKS) Earnings May Just Be The Starting Point

Price target decreased by 7.5% to US$33.10

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkermes plc to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkermes plc to Report Q2, 2023 Results on Jul 26, 2023

Is Alkermes (NASDAQ:ALKS) Using Debt Sensibly?

Forecast breakeven date moved forward to 2023

Sarissa Issues Presentation for Alkermes Shareholders

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Sarissa Capital Management Issues a Presentation to Shareholder of Alkermes plc

Forecast breakeven date moved forward to 2023

Sarissa Capital Issues a Letter to Shareholders of Alkermes

There Is A Reason Alkermes plc's (NASDAQ:ALKS) Price Is Undemanding

Consensus EPS estimates have been upgraded.

Alkermes plc, Annual General Meeting, Jun 29, 2023

Consensus estimates of losses per share improve by 76%

Lead Independent Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Is Alkermes plc (NASDAQ:ALKS) Trading At A 44% Discount?

Does Alkermes (NASDAQ:ALKS) Have A Healthy Balance Sheet?

Chairman & CEO exercised options and sold US$399k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Alkermes plc Provides Earnings Guidance for the Year 2023

Alkermes plc to Report Q4, 2022 Results on Feb 16, 2023

Sarissa Capital Engages with the Alkermes plc

High number of new directors

Alkermes plc Awards Innovation Passport Designation by the MHRA (UK) for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma

Alkermes plc Revises Earnings Guidance for 2022

Alkermes upgraded to neutral at BofA on improved risk/reward outlook

Alkermes holder Sarissa Capital says it may look to increase its stake

Alkermes: Nothing Stands Out As Interesting

Health Check: How Prudently Does Alkermes (NASDAQ:ALKS) Use Debt?

Alkermes initiated at neutral at Piper Sandler as company in transition

Consensus estimates of losses per share improve by 15%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Alkermes plc Revises Earnings Guidance for the Full Year 2022

Alkermes Q2 2022 Earnings Preview

Alkermes plc to Report Q2, 2022 Results on Jul 27, 2022

Alkermes plc, Annual General Meeting, Jul 07, 2022

Sarissa Capital Comments on Alkermes Annual Meeting